Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | LTA4H | P09960 | 3/20 | 0.56 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10132780 | 0.89 | HPGD (0.62) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10133033 | 0.87 | TUBB4A (0.53) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL23291236 | 0.84 | LTA4H (0.59) | MEN1KMT2ARAB9ALTA4HKCNA5 | |
| SCHEMBL10132920 | 0.84 | HRH3 (0.62) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10132985 | 0.81 | LTA4H (0.64) | MEN1KMT2ANPC1RAB9ALTA4H | |
| SCHEMBL3868656 | 0.80 | NPC1 (0.67) | MEN1KMT2ANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11754722 | 0.80 | HDAC2 (0.59) | NPC1RAB9ASMN1; SMN2MAPTDRD3 | |
| SCHEMBL23928134 | 0.79 | RAB9A (0.56) | NPC1RAB9ALTA4HDRD3HPGD | |
| SCHEMBL10132993 | 0.79 | LTA4H (0.61) | MEN1KMT2ANPC1RAB9ALTA4H | |
| SCHEMBL10132964 | 0.78 | TUBB4A (0.63) | MEN1KMT2ANPC1RAB9ALTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124605-B2 | Compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124605-B2 | Compositions and methods for modulating a kinase cascade | KINEX PHARMACEUTICALS, LLC (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | OAKTREE FUND ADMINISTRATION, LLC | 2009-06-11 | — | — | US | disclosed |
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | OAKTREE FUND ADMINISTRATION, LLC | 2009-06-11 | — | — | US | disclosed |
| WO-2009009041-A2 | COMPOSITIONS AND METHODS FOR MODULATING A KINASE CASCADE | KINEX PHARMACEUTICALS, LLC (US) | 2009-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149510-A1 | Compositions and methods for modulating a kinase cascade | MAP3K6, MAP3K4, MAP3K3 | MEN1 2398/4885KMT2A 2598/4885NPC1 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.